FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Elevidys Shipping Nixed After 2nd Liver‑Failure Death

Sarepta Therapeutics halts shipments of its gene therapy Elevidys (delandistrogene moxeparvovec‑rokl) to non‑ambulatory Duchen...

latest-news-card-1
Human Drugs

CGMP Issues at Indias Kenil Healthcare

FDA warns Indias Kenil Private Healthcare about CGMP violations in its production of finished drugs.

latest-news-card-1
Human Drugs

Pfizers Talzenna Gets Updated Label

FDA approves updated labeling on Pfizers s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for men with metastatic castration-resista...

latest-news-card-1
Human Drugs

Commissioners National Priority Voucher Program

FDA launches the Commissioners National Priority Vouchers to speed drug reviews for companies with products that are aligned with national priorities ...

latest-news-card-1
Human Drugs

Aldeyra Files NDA Resubmission for Dry Eye Drug

Aldeyra Therapeutics resubmits an NDA for reproxalap to treat the signs and symptoms of dry eye disease.

latest-news-card-1
Human Drugs

Zhejiang Huahai Pharmaceutical CGMP Issues

FDA warns Chinas Zhejiang Huahai Pharmaceutical Co. about CGMP violations in its production of finished drugs.

latest-news-card-1
Human Drugs

OIG Hit FDA Accelerated Approvals

The latest semiannual report issued by the HHS Office of Inspector General raises questions about specific FDA accelerated drug approvals.

latest-news-card-1
Human Drugs

FDA Allows Companies to Skip Import Bans: Report

A ProPublica investigative report details how a secret small group of FDA officials has approved exemptions for products from overseas factories that ...

latest-news-card-1
Human Drugs

Roche Advancing Parkinsons Drug Into Phase 3

Roche moves prasinezumab into a Phase 3 trial after two mid‑stage trials and their open‑label extensions hinted at a disease‑slowing...

latest-news-card-1
Human Drugs

Milestone Pharma Files NDA Resubmission for Cardamyst

Milestone Pharmaceuticals submits its response to a March-issued FDA complete response letter on the companys NDA for irregular heart beat drug Cardam...